The Experts below are selected from a list of 12792 Experts worldwide ranked by ideXlab platform
Michael J. Rathbone - One of the best experts on this subject based on the ideXlab platform.
-
Fundamentals and Applications of Controlled Release Drug Delivery - Fundamentals and applications of controlled Release Drug delivery
2012Co-Authors: Jürgen Siepmann, Ronald A Siegel, Michael J. RathboneAbstract:The Need for Drugs and Drug Delivery Systems.- Overview of Controlled Release Mechanisms.- Hydrophobic Polymers of Pharmaceutical Significance.- Hydrogels.- Biodegradable Polymers in Drug Delivery Systems.- Diffusion Controlled Drug Delivery Systems.- Swelling Controlled Drug Delivery Systems.- Degradable Polymeric Carriers for Parenteral Controlled Drug Delivery Systems.- Porous Systems.- Targeted Delivery Using Biodegradable polymeric Nanoparticles.- Liposomes in Drug Delivery.- Receptor Mediated Delivery Systems for Cancer Therapeutics.- Biological Rhythms, Drug Delivery, and Chronotherapeutics.- Site Specific Controlled Release for Cardiovascular Disease - Translational Direction.- Drug Delivery Systems to Fight Cancer.- Applications of Vaccine Delivery in Infectious Diseases.- Tissue Engineering in Drug Delivery.- The Shaping of Controlled Release Drug Product Development by Emerging Trends in the Commercial, Regulatory and Political Macro-Environment
-
fundamentals and applications of controlled Release Drug delivery
2012Co-Authors: Jürgen Siepmann, Ronald A Siegel, Michael J. RathboneAbstract:The Need for Drugs and Drug Delivery Systems.- Overview of Controlled Release Mechanisms.- Hydrophobic Polymers of Pharmaceutical Significance.- Hydrogels.- Biodegradable Polymers in Drug Delivery Systems.- Diffusion Controlled Drug Delivery Systems.- Swelling Controlled Drug Delivery Systems.- Degradable Polymeric Carriers for Parenteral Controlled Drug Delivery Systems.- Porous Systems.- Targeted Delivery Using Biodegradable polymeric Nanoparticles.- Liposomes in Drug Delivery.- Receptor Mediated Delivery Systems for Cancer Therapeutics.- Biological Rhythms, Drug Delivery, and Chronotherapeutics.- Site Specific Controlled Release for Cardiovascular Disease - Translational Direction.- Drug Delivery Systems to Fight Cancer.- Applications of Vaccine Delivery in Infectious Diseases.- Tissue Engineering in Drug Delivery.- The Shaping of Controlled Release Drug Product Development by Emerging Trends in the Commercial, Regulatory and Political Macro-Environment
-
Modified-Release Drug Delivery Technology - Modified-Release Drug delivery technology
2002Co-Authors: Michael J. Rathbone, Jonathan Hadgraft, Michael S. RobertsAbstract:Oral modified-Release delivery systems TIMERx oral controlled-Release Drug delivery system MASRx and COSRx sustained-Release technology Procise - Drug delivery systems based on geometric configuration ringcap technology Smartrix system - designcharacteristics and Release properties of a novel erosion-controlled oral delivery system Theriform technology Accudep technology for oral modified Drug Release osmotically controlled tablets three-phase pharmaceutical form - THREEFORM - withcontrolled Release of amorphous active ingredient for once-daily administration.
-
modified Release Drug delivery technology
(2 vols). (2nd ed. ed.). Informa Healthcare: USA. (2008), 2002Co-Authors: Michael J. Rathbone, Jonathan Hadgraft, Michael S. RobertsAbstract:Oral modified-Release delivery systems TIMERx oral controlled-Release Drug delivery system MASRx and COSRx sustained-Release technology Procise - Drug delivery systems based on geometric configuration ringcap technology Smartrix system - design characteristics and Release properties of a novel erosion-controlled oral delivery system Theriform technology Accudep technology for oral modified Drug Release osmotically controlled tablets three-phase pharmaceutical form - THREEFORM - with controlled Release of amorphous active ingredient for once-daily administration.
-
Controlled Release Drug delivery systems for estrous control of domesticated livestock
Controlled Release Veterinary Drug Delivery, 2000Co-Authors: Michael J. Rathbone, Patrick J. Burns, Colin Roger Ogle, Shane Burggraaf, Craig R. BuntAbstract:Publisher Summary The need for controlled Release Drug delivery systems in the field of estrous control of domesticated livestock arises due to the physicochemical and pharmacokinetic characteristics of the Drugs. The first use of controlled Release Drug delivery systems to control the estrous cycle of sheep and cattle dates back to the mid 1960s and mid 1970s, respectively. In spite of the long history associated with this area of Drug delivery, the opportunity to develop and commercialize controlled Release Drug delivery systems to control the estrous cycle of domesticated species has never been greater. This is because of the rise in on-farm use of procedures such as embryo transfer and new assisted reproductive technologies. This chapter describes the controlled Release Drug delivery systems which are currently available or in development for the control of the estrous cycle in sheep, cattle, pigs, and horses. It describes some of the formulation considerations for such products and highlights recent advances in the field of estrous control in horses and pigs.
Philippe Renaud - One of the best experts on this subject based on the ideXlab platform.
-
Controlled Release Drug Coatings on Flexible Neural Probes
2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007Co-Authors: Andre Mercanzini, Sai Reddy, Diana Velluto, Philippe Colin, Anne Maillard, Jean-charles Bensadoun, Arnaud Bertsch, Jeffrey A. Hubbell, Philippe RenaudAbstract:We present the development, characterization and in vivo validation of a novel Drug eluting coating that has been applied to flexible neural probes. The coating consists of Drug eluting nanoparticles loaded with an anti-inflammatory Drug embedded in a biodegradable polymer. The Drug eluting coating is applied to flexible polymer neural probes with platinum electrodes. The Drug eluting device is implanted in one hemisphere of a rat, while a control device is implanted in the opposite hemisphere. Impedance measurements are performed to determine the effect of the Drug eluting coating on the tissue reaction surrounding the probe and the electrical characteristics of the devices. Probes that are coated with Drug eluting coatings show better long term impedance characteristics over control probes. These coatings can be used to increase the reliability and long term success of neural prostheses.
Seán Mcloone - One of the best experts on this subject based on the ideXlab platform.
-
CASE - Slow Release Drug dissolution profile prediction in pharmaceutical manufacturing: A multivariate and machine learning approach
2015 IEEE International Conference on Automation Science and Engineering (CASE), 2015Co-Authors: Gian Antonio Susto, Seán MclooneAbstract:Slow Release Drugs must be manufactured to meet target specifications with respect to dissolution curve profiles. In this paper we consider the problem of identifying the drivers of dissolution curve variability of a Drug from historical manufacturing data. Several data sources are considered: raw material parameters, coating data, loss on drying and pellet size statistics. The methodology employed is to develop predictive models using LASSO, a powerful machine learning algorithm for regression with high-dimensional datasets. LASSO provides sparse solutions facilitating the identification of the most important causes of variability in the Drug fabrication process. The proposed methodology is illustrated using manufacturing data for a slow Release Drug.
-
Slow Release Drug dissolution profile prediction in pharmaceutical manufacturing: A multivariate and machine learning approach
2015 IEEE International Conference on Automation Science and Engineering (CASE), 2015Co-Authors: Gian Antonio Susto, Seán MclooneAbstract:Slow Release Drugs must be manufactured to meet target specifications with respect to dissolution curve profiles. In this paper we consider the problem of identifying the drivers of dissolution curve variability of a Drug from historical manufacturing data. Several data sources are considered: raw material parameters, coating data, loss on drying and pellet size statistics. The methodology employed is to develop predictive models using LASSO, a powerful machine learning algorithm for regression with high-dimensional datasets. LASSO provides sparse solutions facilitating the identification of the most important causes of variability in the Drug fabrication process. The proposed methodology is illustrated using manufacturing data for a slow Release Drug.
Fiorenzo G Omenetto - One of the best experts on this subject based on the ideXlab platform.
-
fabrication of silk microneedles for controlled Release Drug delivery
Advanced Functional Materials, 2012Co-Authors: Konstantinos Tsioris, Waseem K Raja, Eleanor M Pritchard, Bruce Panilaitis, David L Kaplan, Fiorenzo G OmenettoAbstract:Microneedles are emerging as a minimally invasive Drug delivery alternative to hypodermic needles. Current material systems utilized in microneedles impose constraints hindering the further development of this technology. In particular, it is difficult to preserve sensitive biochemical compounds (such as pharmaceuticals) during processing in a single microneedle system and subsequently achieve their controlled Release. A possible solution involves fabricating microneedles systems from the biomaterial silk fibroin. Silk fibroin combines excellent mechanical properties, biocompatibility, biodegradability, benign processing conditions, and the ability to preserve and maintain the activity of biological compounds entrained in its material matrix. The degradation rate of silk fibroin and the diffusion rate of the entrained molecules can be controlled simply by adjusting post-processing conditions. This combination of properties makes silk an ideal choice to improve on existing issues associated with other microneedle-based Drug delivery system. In this study, a fabrication method to produce silk biopolymer microstructures with the high aspect ratios and mechanical properties required to manufacture microneedle systems is reported. Room temperature and aqueous-based micromolding allows for the bulk loading of these microneedles with labile Drugs. The Drug Release rate is decreased 5.6-fold by adjusting the post-processing conditions of the microneedles, mainly by controlling the silk protein secondary structure. The Release kinetics are quantified in an in vitro collagen hydrogel model, which allows tracking of the model Drug. Antibiotic loaded silk microneedles are manufactured and used to demonstrate a 10-fold reduction of bacterial density after their application. The processing strategies developed in this study can be expanded to other silk-based structural formats for Drug delivery and biologicals storage applications.
Mark Staples - One of the best experts on this subject based on the ideXlab platform.
-
Microchips and controlled-Release Drug reservoirs
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2010Co-Authors: Mark StaplesAbstract:This review summarizes and updates the development of implantable microchip-containing devices that control dosing from Drug reservoirs integrated with the devices. As the expense and risk of new Drug development continues to increase, technologies that make the best use of existing therapeutics may add significant value. Trends of future medical care that may require advanced Drug delivery systems include individualized therapy and the capability to automate Drug delivery. Implantable Drug delivery devices that promise to address these anticipated needs have been constructed in a variety of ways using micro- and nanoelectromechanical systems (MEMS or NEMS)-based technology. These devices expand treatment options for addressing unmet medical needs related to dosing. Within the last few years, advances in several technologies (MEMS or NEMS fabrication, materials science, polymer chemistry, and data management) have converged to enable the construction of miniaturized implantable devices for controlled delivery of therapeutic agents from one or more reservoirs. Suboptimal performance of conventional dosing methods in terms of safety, efficacy, pain, or convenience can be improved with advanced delivery devices. Microchip-based implantable Drug delivery devices allow localized delivery by direct placement of the device at the treatment site, delivery on demand (emergency administration, pulsatile, or adjustable continuous dosing), programmable dosing cycles, automated delivery of multiple Drugs, and dosing in response to physiological and diagnostic feedback. In addition, innovative Drug-medical device combinations may protect labile active ingredients within hermetically sealed reservoirs.
